Amgen (NASDAQ: AMGN) will present data from four Phase 2 trials of AMG 145, an investigational fully human monoclonal antibody directed against PCSK9, a protein that reduces the liver's ability to remove low density lipoprotein cholesterol (LDL-C), or "bad" cholesterol from the blood, at the upcoming American Heart Association (AHA) Scientific Sessions 2012.
Selected abstracts of interest that will be presented at the meeting include:
-
Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD): Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
Late-Breaking Clinical Trials, Monday, Nov. 05, 10:50 a.m. – 11:00 a.m. (Hall G)
-
Goal Achievement after Utilizing an Anti-PCSK9 in Statin Intolerant Subjects (GAUSS): Results from a Randomized, Double-blind, Placebo controlled Study
Late-Breaking Clinical Trials, Monday, Nov. 05, 11:00 a.m. – 11:10 a.m. (Hall G)
-
LAPLACE-TIMI 57 Primary Results
Clinical Science: Special Reports, Tuesday, Nov. 06, 7:45 a.m. – 7:55 a.m. (Petree Hall D)
-
Efficacy and Safety of a Fully Human Monoclonal Antibody Against PCSK9 as Monotherapy for Hypercholesterolemia: Results from the MENDEL Study, a Global Phase 2 Trial of AMG 145
Clinical Science: Special Reports, Tuesday, Nov. 06, 7:55 a.m. – 8:05 a.m. (Petree Hall D)
Interferon-beta deficiency alters brain response in neuroHIV mouse model